O	0	12	Differential	Differential	JJ	B-NP
O	13	23	expression	expression	NN	I-NP
O	24	27	and	and	CC	O
O	28	36	mutation	mutation	NN	B-NP
O	37	39	of	of	IN	B-PP
O	40	43	NME	NME	NN	B-NP
O	44	49	genes	gene	NNS	I-NP
O	50	52	in	in	IN	B-PP
O	53	63	autologous	autologous	JJ	B-NP
O	64	72	cultured	culture	VBN	I-NP
O	73	78	human	human	JJ	I-NP
B-Cell	79	87	melanoma	melanoma	NN	I-NP
I-Cell	88	93	cells	cell	NNS	I-NP
O	94	98	with	with	IN	B-PP
O	99	108	different	different	JJ	B-NP
O	109	119	metastatic	metastatic	JJ	I-NP
O	120	130	potentials	potential	NNS	I-NP
O	130	131	.	.	.	O

O	133	136	The	The	DT	B-NP
O	137	145	putative	putative	JJ	I-NP
O	146	156	metastasis	metastasis	NN	I-NP
O	157	167	suppressor	suppressor	NN	I-NP
O	168	173	genes	gene	NNS	I-NP
O	173	174	,	,	,	O
O	175	179	NME1	NME1	NN	B-NP
O	179	180	(	(	(	O
O	180	184	nm23	nm23	NN	B-NP
O	184	185	-	-	HYPH	B-NP
O	185	186	1	1	CD	I-NP
O	186	187	)	)	)	O
O	188	191	and	and	CC	O
O	192	196	NME2	NME2	NN	B-NP
O	196	197	(	(	(	O
O	197	201	nm23	nm23	NN	B-NP
O	201	202	-	-	HYPH	O
O	202	203	2	2	CD	B-NP
O	203	204	)	)	)	O
O	204	205	,	,	,	O
O	206	210	were	be	VBD	B-VP
O	211	219	examined	examine	VBN	I-VP
O	220	222	in	in	IN	B-PP
O	223	224	a	a	DT	B-NP
O	225	230	model	model	NN	I-NP
O	231	237	system	system	NN	I-NP
O	238	240	we	we	PRP	B-NP
O	241	250	developed	develop	VBD	B-VP
O	251	253	to	to	TO	I-VP
O	254	265	approximate	approximate	VB	I-VP
O	266	269	the	the	DT	B-NP
O	270	283	dissemination	dissemination	NN	I-NP
O	284	286	of	of	IN	B-PP
B-Cancer	287	295	melanoma	melanoma	NN	B-NP
O	296	300	from	from	IN	B-PP
O	301	302	a	a	DT	B-NP
B-Cancer	303	310	primary	primary	JJ	I-NP
I-Cancer	311	315	skin	skin	NN	I-NP
I-Cancer	316	321	tumor	tumor	NN	I-NP
O	321	322	.	.	.	O

O	323	325	We	We	PRP	B-NP
O	326	334	utilized	utilize	VBD	B-VP
O	335	338	two	two	CD	B-NP
O	339	349	autologous	autologous	JJ	I-NP
O	350	355	human	human	JJ	I-NP
B-Cell	356	364	melanoma	melanoma	NN	I-NP
I-Cell	365	369	cell	cell	NN	I-NP
I-Cell	370	375	lines	line	NNS	I-NP
O	375	376	,	,	,	O
B-Cell	377	379	IV	IV	CD	B-NP
I-Cell	380	382	Cl	Cl	NN	I-NP
I-Cell	383	384	1	1	CD	B-NP
O	385	388	and	and	CC	I-NP
B-Cell	389	391	IV	IV	CD	I-NP
I-Cell	392	394	Cl	Cl	NN	I-NP
I-Cell	395	396	3	3	CD	I-NP
O	396	397	,	,	,	O
O	398	403	which	which	WDT	B-NP
O	404	413	displayed	display	VBD	B-VP
O	414	427	qualitatively	qualitatively	RB	B-NP
O	428	437	different	different	JJ	I-NP
O	438	448	metastatic	metastatic	JJ	I-NP
O	449	459	phenotypes	phenotype	NNS	I-NP
O	460	469	following	follow	VBG	B-PP
B-Organism_subdivision	470	479	subdermal	subdermal	JJ	B-NP
O	480	491	inoculation	inoculation	NN	I-NP
O	492	496	into	into	IN	B-PP
O	497	501	nude	nude	JJ	B-NP
O	502	506	mice	mouse	NNS	I-NP
O	506	507	.	.	.	O

O	508	514	Highly	Highly	RB	B-NP
B-Cell	515	525	metastatic	metastatic	JJ	I-NP
I-Cell	526	528	IV	IV	CD	I-NP
I-Cell	529	531	Cl	Cl	NN	I-NP
I-Cell	532	533	1	1	CD	B-NP
I-Cell	534	539	cells	cell	NNS	I-NP
O	540	549	expressed	express	VBD	B-VP
O	550	563	approximately	approximately	RB	B-NP
O	564	565	5	5	CD	I-NP
O	566	570	fold	fold	JJ	I-NP
O	571	576	lower	low	JJR	I-NP
O	577	583	levels	level	NNS	I-NP
O	584	586	of	of	IN	B-PP
O	587	594	protein	protein	NN	B-NP
O	595	602	encoded	encode	VBN	B-VP
O	603	605	by	by	IN	B-PP
O	606	609	NME	NME	NN	B-NP
O	610	615	genes	gene	NNS	I-NP
O	616	620	than	than	IN	B-PP
B-Cell	621	624	non	non	AFX	B-NP
I-Cell	624	625	-	-	HYPH	B-NP
I-Cell	625	635	metastatic	metastatic	JJ	I-NP
I-Cell	636	638	IV	IV	CD	I-NP
I-Cell	639	641	Cl	Cl	NN	I-NP
I-Cell	642	643	3	3	CD	B-NP
I-Cell	644	649	cells	cell	NNS	I-NP
O	649	650	.	.	.	O

O	651	658	Similar	Similar	JJ	B-NP
O	659	670	differences	difference	NNS	I-NP
O	671	673	in	in	IN	B-PP
O	674	677	NME	NME	NN	B-NP
O	678	685	protein	protein	NN	I-NP
O	686	692	levels	level	NNS	I-NP
O	693	697	were	be	VBD	B-VP
O	698	706	observed	observe	VBN	I-VP
O	707	709	in	in	IN	B-PP
B-Cancer	710	716	tumors	tumor	NNS	B-NP
O	717	724	induced	induce	VBN	B-VP
O	725	727	by	by	IN	B-PP
O	728	731	the	the	DT	B-NP
O	732	735	two	two	CD	I-NP
B-Cell	736	740	cell	cell	NN	I-NP
I-Cell	741	746	lines	line	NNS	I-NP
O	747	749	in	in	IN	B-PP
O	750	754	nude	nude	JJ	B-NP
O	755	759	mice	mouse	NNS	I-NP
O	759	760	.	.	.	O

O	761	766	There	There	EX	B-NP
O	767	771	were	be	VBD	B-VP
O	772	774	no	no	DT	B-NP
O	775	786	differences	difference	NNS	I-NP
O	787	789	in	in	IN	B-PP
O	790	793	NME	NME	NN	B-NP
O	794	798	mRNA	mRNA	NN	I-NP
O	799	805	levels	level	NNS	I-NP
O	806	813	between	between	IN	B-PP
O	814	819	these	these	DT	B-NP
O	820	823	two	two	CD	I-NP
B-Cell	824	828	cell	cell	NN	I-NP
I-Cell	829	834	lines	line	NNS	I-NP
O	834	835	,	,	,	O
O	836	846	suggesting	suggest	VBG	B-VP
O	847	851	that	that	IN	B-SBAR
O	852	862	expression	expression	NN	B-NP
O	863	865	of	of	IN	B-PP
O	866	871	these	these	DT	B-NP
O	872	880	proteins	protein	NNS	I-NP
O	881	883	is	be	VBZ	B-VP
O	884	893	regulated	regulate	VBN	I-VP
O	894	896	at	at	IN	B-PP
O	897	898	a	a	DT	B-NP
O	899	903	post	post	AFX	I-NP
O	903	904	-	-	HYPH	I-NP
O	904	919	transcriptional	transcriptional	JJ	I-NP
O	920	925	level	level	NN	I-NP
O	925	926	.	.	.	O

O	927	929	We	We	PRP	B-NP
O	930	935	found	find	VBD	B-VP
O	936	937	a	a	DT	B-NP
O	938	944	ser122	ser122	NN	I-NP
O	944	945	-	-	HYPH	B-NP
O	945	948	pro	pro	JJ	I-NP
O	949	957	mutation	mutation	NN	I-NP
O	958	960	in	in	IN	B-PP
O	961	964	the	the	DT	B-NP
O	965	969	NME2	NME2	NN	I-NP
O	970	974	gene	gene	NN	I-NP
O	975	977	of	of	IN	B-PP
B-Cell	978	988	metastatic	metastatic	JJ	B-NP
I-Cell	989	991	IV	IV	CD	I-NP
I-Cell	992	994	Cl	Cl	NN	I-NP
I-Cell	995	996	1	1	CD	B-NP
I-Cell	997	1002	cells	cell	NNS	I-NP
O	1002	1003	.	.	.	O

O	1004	1005	A	A	DT	B-NP
O	1006	1013	similar	similar	JJ	I-NP
O	1014	1020	ser120	ser120	NN	I-NP
O	1020	1021	-	-	HYPH	I-NP
O	1021	1024	gly	gly	NN	I-NP
O	1025	1033	mutation	mutation	NN	I-NP
O	1034	1036	in	in	IN	B-PP
O	1037	1041	NME1	NME1	NN	B-NP
O	1042	1045	has	have	VBZ	B-VP
O	1046	1050	been	be	VBN	I-VP
O	1051	1056	found	find	VBN	I-VP
O	1057	1059	in	in	IN	B-PP
O	1060	1065	human	human	JJ	B-NP
B-Cancer	1066	1079	neuroblastoma	neuroblastoma	NN	I-NP
O	1079	1080	,	,	,	O
O	1081	1091	suggesting	suggest	VBG	B-VP
O	1092	1096	that	that	IN	B-SBAR
O	1097	1105	mutation	mutation	NN	B-NP
O	1106	1108	in	in	IN	B-PP
O	1109	1113	this	this	DT	B-NP
O	1114	1120	region	region	NN	I-NP
O	1121	1124	may	may	MD	B-VP
O	1125	1127	be	be	VB	I-VP
O	1128	1129	a	a	DT	B-NP
O	1130	1137	general	general	JJ	I-NP
O	1138	1148	phenomenon	phenomenon	NN	I-NP
O	1149	1156	related	relate	VBN	B-VP
O	1157	1159	to	to	TO	B-PP
B-Cancer	1160	1165	tumor	tumor	NN	B-NP
O	1166	1177	progression	progression	NN	I-NP
O	1177	1178	.	.	.	O

O	1179	1184	These	These	DT	B-NP
O	1185	1194	mutations	mutation	NNS	I-NP
O	1195	1198	may	may	MD	B-VP
O	1199	1203	have	have	VB	I-VP
O	1204	1214	functional	functional	JJ	B-NP
O	1215	1227	consequences	consequence	NNS	I-NP
O	1228	1233	since	since	IN	B-SBAR
O	1234	1238	they	they	PRP	B-NP
O	1239	1248	eliminate	eliminate	VBP	B-VP
O	1249	1258	potential	potential	JJ	B-NP
O	1259	1274	phosphorylation	phosphorylation	NN	I-NP
O	1275	1280	sites	site	NNS	I-NP
O	1281	1284	and	and	CC	O
O	1285	1288	may	may	MD	B-VP
O	1289	1295	affect	affect	VB	I-VP
O	1296	1299	the	the	DT	B-NP
O	1300	1308	tertiary	tertiary	JJ	I-NP
O	1309	1318	structure	structure	NN	I-NP
O	1319	1321	of	of	IN	B-PP
O	1322	1328	mature	mature	JJ	B-NP
O	1329	1336	protein	protein	NN	I-NP
O	1337	1346	complexes	complex	NNS	I-NP
O	1346	1347	.	.	.	O

